

JAN 14 2005

Appl. No. 09/806,703

AMENDMENTS TO THE SPECIFICATION

Please replace the first paragraph on page 1, line 1 with the following amended paragraph:

This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/DK99/00525 which has an International filing date of October 5, 1999, which designated the United States of America. This application also claims priority under 35 U.S.C. § 119(e) on U.S. Provisional Application No. 60/105,011 filed on October 20, 1998, ~~the entire contents of which are hereby incorporated by reference.~~

Please replace the paragraph on page 119 beginning on line 22 with the following amended paragraph:

According to our expectation that the autovaccine will induce a CTL response, it would be important to identify and preserve potentially subdominant CTL epitopes in the constructs. Two such epitopes are already known from the literature: 1) the peptide comprising LLHETDSAV, which is amino acids 4-12 of PSM (SEQ ID NO:1), ~~amino acids 4-12 (LLHETDSAV)~~ can be presented on the human MHC class I molecule HLA-A2.1 (Tjoa 1996), and 2) the peptide comprising ALFDIESKV, which is amino acids 711-719 of PMS (SEQ ID NO:1), ~~(711-719) (ALFDIESKV)~~ also binds HLA-A2.1 (ref 25). We have

Appl. No. 09/806,703

also searched the PSM amino acid sequence in order to identify primary anchor residues of HLA class I binding motifs as described by Rammensee et al. (Rammensee, 1995) for the most abundant HLA class I types (HLA-A1, HLA-A2, HLA-A3, HLA-A23, HLA-A24 and HLA-A28), together constituting 80% of the HLA-A types of the human population. Likewise, potential HLA-B and HLA-C epitopes have been identified and designated as "forbidden" areas.